Ask what happens to appetite after stopping GLP-1 medication and you will get a confident answer almost anywhere you look. Nobody measured it. The three landmark withdrawal trials recorded body weight and cardiometabolic markers, and not appetite, hunger, craving or food intake — not one of them. This article covers what was actually measured, what the pharmacology implies, and why the gap between those two things is worth understanding rather than papering over.

Withdrawal trial: a study in which people who lost weight on a medication are switched to placebo. The three main ones here are the STEP 1 extension, STEP 4 and SURMOUNT-4.

What the withdrawal trials measured

Weight, and markers. That is the list.

The STEP 1 extension followed 327 participants for a year off treatment and reported that they regained about two-thirds of their lost weight, with cardiometabolic improvements reverting towards baseline for most variables (Wilding 2022). STEP 4 reported a mean 6.9% regain over 48 weeks in those switched to placebo against a further 7.9% loss in those continuing (Rubino 2021). SURMOUNT-4 likewise reported weight outcomes.

None of the three reported an appetite, hunger, craving or energy-intake outcome after discontinuation.

Appetite measurement is intensive — laboratory test meals or validated questionnaires — and it was generally done during treatment rather than in the follow-up period after treatment ended.

So: if you read that "cravings come roaring back" and it is attributed to these trials, the attribution is wrong. They did not look.

What was measured, during treatment

The picture on-treatment is much better documented, and it is worth knowing because it frames the inference.

In a crossover trial, semaglutide reduced total food intake across a single laboratory test day by about 24% compared with placebo (Blundell 2017) — a laboratory measurement, not tracked daily eating. In the STEP 5 sub-study, craving-control scores on a self-report instrument improved significantly versus placebo at weeks 20, 52 and 104 (STEP 5 sub-study). Those are mean differences on a questionnaire, not the elimination of cravings.

So the medication demonstrably changes appetite and craving measures while it is being taken. What happens to those measures afterwards was not followed.

What the pharmacology implies

Semaglutide has an elimination half-life of approximately one week, and the label states that it "will be present in the circulation for about 5 to 7 weeks after the last dose of 2.4 mg". Tirzepatide's elimination half-life is approximately 5 to 6 days (labels).

The medication therefore leaves the body over weeks rather than days. Since the appetite effect is produced by the drug acting on receptors, it is reasonable to expect that effect to diminish as the drug clears.

Two caveats matter. Half-life describes drug concentration, not the duration of downstream physiological effect — those can differ. And nobody has measured the time course of appetite return, so "over several weeks" is an inference from clearance rather than an observed finding.

What we can say is that the weight data are consistent with the appetite effect ending: weight starts moving back up after treatment stops (Wilding 2022).

Why the distinction is worth making

Because it changes what you plan for.

If appetite return were a documented, characterised process with a known timeline, you could plan around the timeline. It is not, so you cannot. What you can plan around is the thing the trials did establish: weight returns, and it starts returning promptly.

There is also a physiological headwind independent of the medication. After weight loss, reduced body weight is defended by a coordinated set of metabolic, neuroendocrine and behavioural responses opposing sustained weight loss (Rosenbaum 2010). So someone coming off medication is meeting two things at once — the loss of the drug effect, and the body's own response to having lost weight. Neither has been separated from the other in a withdrawal trial.

We cover the regain data itself in why two-thirds of the weight comes back.

What to do with an unmeasured variable

Build the things that do not depend on appetite being suppressed.

An eating pattern that has become ordinary rather than effortful does not stop working when a prescription ends. A training habit that is already automatic does not require motivation to restart. And the lean mass you carry into that phase is the lean mass you kept — across 114 trials covering 4,184 people, lean mass was statistically unchanged where resistance training accompanied caloric restriction (Lopez 2022).

None of that is a substitute for the appetite effect. It is the set of things that still exist once the appetite effect is gone, and it takes months to establish, which is why it belongs at the start of treatment rather than at the end.

At GetLean, our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. On this particular question that philosophy is doing something concrete: since nobody can tell you what your appetite will do, the sensible move is to build what does not depend on knowing.

Individual results vary, and clinical-trial figures describe the populations studied. Stopping or changing a prescribed medication is a decision to make with your doctor.

Common questions

Does appetite come back after stopping GLP-1 medication?

Almost certainly, and no withdrawal trial measured it. The STEP 1 extension, STEP 4 and SURMOUNT-4 all measured body weight and cardiometabolic markers rather than appetite, hunger or intake. The expectation rests on the drug clearing, not on a trial finding.

How long does GLP-1 medication stay in your system?

Semaglutide's elimination half-life is about one week, and the label states it is present in the circulation for roughly 5 to 7 weeks after a last 2.4 mg dose. Tirzepatide's is about 5 to 6 days (labels).

Will cravings return exactly as before?

Nobody has measured it. What is documented is that craving-control scores improved on treatment (STEP 5 sub-study) and that weight returns after stopping (Wilding 2022).

How quickly does appetite change after the last dose?

Not measured. Half-life tells you how long the drug is present, not how quickly the effect fades — those are different things (labels).

What can you actually do about it?

Build the eating pattern and training habit while appetite is still suppressed, and protect the lean mass you take into that phase — resistance training kept lean mass statistically unchanged across 114 trials (Lopez 2022).